
D +366
|
Day 2 May 21(Fri) 09:00-10:00 |
Oral Presentation 1 [Clinical]
Room 1 |
|---|
| 09:00-09:10 | Evaluation of the Efficacy of ZOledronic Acid Administered Once or Twice after Different Durations of DenosuMab Treatment in Postmenopausal Women with Osteoporosis (ZOOM): A Prospective, Single-Center, Open-Label, Phase IV Study Sung Joon Cho (Yonsei University, Korea) |
|---|---|
| 09:10-09:20 | Impact Of Digital Rehabilitation Modalities: AI-Driven Rehabilitation Versus Augmented Reality Rehabilitation on Bone Mineral Density, Physical and Muscle-Bone Biomarkers in Older Adults with Osteosarcopenia - A Randomized Control Trial Gopal Nambi (Prince Sattam bin Abdulaziz University, Saudi Arabia) |
| 09:20-09:30 | Longitudinal Deterioration in Nutritional Status and Its Association with Increased Risk of Sarcopenia in Community-Dwelling Aged Adults Ho Jun Lim (Seoul National University, Korea) |
| 09:30-09:40 | he Potential Role of Calcitriol in Maintaining Calcium Levels in Osteoporosis Patients Sarcopenia in Community-Dwelling Aged Adults Sung Joon Cho (Yonsei University, Korea) |
| 09:40-09:50 | Impact of Smoking, Diabetes, and Exercise on Dementia Risk in Women with Osteoporosis: A Nationwide Cohort Study Hee Jung Son (Eulji University, Korea) |
| 09:50-10:00 | Comparison of Radiological and Functional Outcomes of Conservative Treatment with Teriparatide and Denosumab in Thoracolumbar Osteoporotic Vertebral Fracture Ikchan Jeon (Yeungnam University, Korea) |
|
Day 2 May 21(Fri) 10:05-10:55 |
Plenary Lecture 1
Room 1 |
|---|
| 10:05-10:55 | Cancer-Associated Muscle Dysfunction: What’s Bone Got to Do With It? Theresa A. Guise (The University of Texas MD Anderson Cancer Center, USA) |
|---|
|
Day 2 May 21(Fri) 11:10-12:25 |
Symposium 1. Antiresorptives: What We’ve Learned and What Lies Ahead
Room 1 |
|---|
| 11:10-11:35 | Denosumab Beyond 10 Years: Balancing Long-Term Benefits and Risks Michael R McClung (Oregon Osteoporosis Center, USA) |
|---|---|
| 11:35-12:00 | Timing Matters in Denosumab: Planning Ahead to Prevent Rebound Fractures Kyoung Min Kim (Yonsei University, Korea) |
| 12:00-12:25 | Beyond Bone Health: Exploring the Mortality Impact of Antiresorptive Therapy Kyoung Jin Kim (Korea University, Korea) |
|
Day 2 May 21(Fri) 12:25-12:40 |
Luncheon Symposium 1 [Amgen]
Room 1 |
|---|
| 12:25-12:40 | Optimal Sequencing in Osteoporosis Care Michael R McClung (Oregon Osteoporosis Center, USA) |
|---|
|
Day 2 May 21(Fri) 12:40-12:55 |
Luncheon Symposium 3 [Yuyu Pharma]
Room 1 |
|---|
| 12:40-12:55 | Efficacy of Different Anti-Resorptive Therapies Following Denosumab Disco A Multicenter Real-World Study in Korea (MAXCARE Study) Hyo-Jeong Kim (Eulji University, Korea) |
|---|
|
Day 2 May 21(Fri) 13:25-14:40 |
Symposium 3. Keynote Symposium
AI in Action: Transforming Translational and Clinical Paradigms Room 1 |
|---|
| 13:25-13:50 | AI-Driven Drug Discovery in the Large Language Model Era Jaewoo Kang (Korea University, Korea) |
|---|---|
| 13:50-14:15 | Incorporating AI in Assessing Fracture Risk: Predicting the Unpredictable Sung Hye Kong (Seoul National University, Korea) |
| 14:15-14:40 | Developing AI-Driven Digital Biomarkers for Sarcopenia Detection Jun-Il Yoo (Inha University, Korea) |
|
Day 2 May 21(Fri) 14:40-15:30 |
Plenary Lecture 2
Room 1 |
|---|
| 14:40-15:30 | Advances in Fracture Risk Assessment: Clinical Applications and Future Directions William D. Leslie (University of Manitoba, Canada) |
|---|
|
Day 2 May 21(Fri) 15:45-17:00 |
KSBMR-ASBMR-JSBMR Joint Symposium
Room 1 |
|---|
| 15:45-16:10 | Immunoporosis: The Regulatory Role of TACE (ADAM17) in Inflammation-Mediated Bone Loss Se Hwan Mun (Sookmyung Women’s University, Korea) |
|---|---|
| 16:10-16:35 | Osteoclast Specific Signatures Kyung Hyun Park-Min (Weill Cornell Medical College, USA) |
| 16:35-17:00 | Skeletal Stem Cell Landscape: The Dual Fates of Regeneration and Exhaustion Yuki Matsushita (Nagasaki University, Japan) |